Trends in short-term survival from distant-stage cutaneous melanoma in the United States, 2001-2013 (CONCORD-3).
Journal
JNCI cancer spectrum
ISSN: 2515-5091
Titre abrégé: JNCI Cancer Spectr
Pays: England
ID NLM: 101721827
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
05
02
2020
revised:
13
07
2020
accepted:
19
08
2020
entrez:
7
1
2021
pubmed:
8
1
2021
medline:
8
1
2021
Statut:
epublish
Résumé
Survival from metastatic cutaneous melanoma is substantially lower than for localized disease. Treatments for metastatic melanoma have been limited, but remarkable clinical improvements have been reported in clinical trials in the last decade. We described the characteristics of US patients diagnosed with cutaneous melanoma during 2001-2013 and assessed trends in short-term survival for distant-stage disease. Trends in 1-year net survival were estimated using the Pohar Perme estimator, controlling for background mortality with life tables of all-cause mortality rates by county of residence, single year of age, sex, and race for each year 2001-2013. We fitted a flexible parametric survival model on the log-hazard scale to estimate the effect of race on the hazard of death because of melanoma and estimated 1-year net survival by race. Only 4.4% of the 425 915 melanomas were diagnosed at a distant stage, cases diagnosed at a distant stage are more commonly men, older patients, and African Americans. Age-standardized, 1-year net survival for distant-stage disease was stable at approximately 43% during 2001-2010. From 2010 onward, survival improved rapidly, reaching 58.9% (95% confidence interval = 56.6% to 61.2%) for patients diagnosed in 2013. Younger patients experienced the largest improvement. Survival for distant-stage disease increased in both Blacks and Whites but was consistently lower in Blacks. One-year survival for distant-stage melanoma improved during 2001-2013, particularly in younger patients and those diagnosed since 2010. This improvement may be a consequence of the introduction of immune-checkpoint-inhibitors and other targeted treatments for metastatic and unresectable disease. Persistent survival inequalities exist between Blacks and Whites, suggesting differential access to treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Survival from metastatic cutaneous melanoma is substantially lower than for localized disease. Treatments for metastatic melanoma have been limited, but remarkable clinical improvements have been reported in clinical trials in the last decade. We described the characteristics of US patients diagnosed with cutaneous melanoma during 2001-2013 and assessed trends in short-term survival for distant-stage disease.
METHODS
METHODS
Trends in 1-year net survival were estimated using the Pohar Perme estimator, controlling for background mortality with life tables of all-cause mortality rates by county of residence, single year of age, sex, and race for each year 2001-2013. We fitted a flexible parametric survival model on the log-hazard scale to estimate the effect of race on the hazard of death because of melanoma and estimated 1-year net survival by race.
RESULTS
RESULTS
Only 4.4% of the 425 915 melanomas were diagnosed at a distant stage, cases diagnosed at a distant stage are more commonly men, older patients, and African Americans. Age-standardized, 1-year net survival for distant-stage disease was stable at approximately 43% during 2001-2010. From 2010 onward, survival improved rapidly, reaching 58.9% (95% confidence interval = 56.6% to 61.2%) for patients diagnosed in 2013. Younger patients experienced the largest improvement. Survival for distant-stage disease increased in both Blacks and Whites but was consistently lower in Blacks.
CONCLUSIONS
CONCLUSIONS
One-year survival for distant-stage melanoma improved during 2001-2013, particularly in younger patients and those diagnosed since 2010. This improvement may be a consequence of the introduction of immune-checkpoint-inhibitors and other targeted treatments for metastatic and unresectable disease. Persistent survival inequalities exist between Blacks and Whites, suggesting differential access to treatment.
Identifiants
pubmed: 33409455
doi: 10.1093/jncics/pkaa078
pii: pkaa078
pmc: PMC7771008
doi:
Types de publication
Journal Article
Langues
eng
Pagination
pkaa078Subventions
Organisme : NCI NIH HHS
ID : P30 CA086862
Pays : United States
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press.
Références
Medicine (Baltimore). 2017 Apr;96(15):e6258
pubmed: 28403068
Cancer Med. 2017 Oct;6(10):2203-2212
pubmed: 28879661
J Immunother. 2019 Jul/Aug;42(6):228-235
pubmed: 30985445
Cancer Causes Control. 1997 Mar;8(2):246-52
pubmed: 9134249
J Am Acad Dermatol. 2011 Nov;65(5 Suppl 1):S78-86
pubmed: 22018071
N Engl J Med. 2016 Nov 10;375(19):1845-1855
pubmed: 27717298
Medicine (Baltimore). 2016 Apr;95(17):e3315
pubmed: 27124020
Lancet Oncol. 2010 Feb;11(2):155-64
pubmed: 20004617
J Am Acad Dermatol. 1996 Jun;34(6):962-70
pubmed: 8647989
Eur J Cancer Prev. 2016 Sep;25(5):404-9
pubmed: 26266895
N Engl J Med. 2005 Oct 27;353(17):1784-92
pubmed: 16251534
Br J Cancer. 2015 Mar 31;112 Suppl 1:S116-23
pubmed: 25734390
J Natl Cancer Inst Monogr. 2014 Nov;2014(49):210-7
pubmed: 25417234
Clin Oncol (R Coll Radiol). 2018 Oct;30(10):609-617
pubmed: 30196844
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
J Clin Oncol. 2007 May 10;25(14):1858-69
pubmed: 17488984
Cancer. 2007 Sep 1;110(5):973-9
pubmed: 17647245
Gynecol Oncol. 2004 Aug;94(2):368-74
pubmed: 15297174
J Am Acad Dermatol. 2011 Nov;65(5 Suppl 1):S26-37
pubmed: 22018064
J Am Acad Dermatol. 2010 May;62(5):777-84
pubmed: 20219266
Cancer Epidemiol. 2015 Feb;39(1):1-7
pubmed: 25468643
Int J Cancer. 2016 Dec 15;139(12):2722-2729
pubmed: 27563839
BMC Cancer. 2016 Aug 30;16:691
pubmed: 27576582
Oncol Res Treat. 2017;40(4):174-183
pubmed: 28376479
Acta Oncol. 2017 Jan;56(1):52-58
pubmed: 27796149
N Engl J Med. 2011 Jun 30;364(26):2507-16
pubmed: 21639808
Haematologica. 2008 Oct;93(10):1544-9
pubmed: 18641022
J Skin Cancer. 2015;2015:505302
pubmed: 26171248
J Am Acad Dermatol. 2004 Jan;50(1):21-4; discussion 142-3
pubmed: 14699360
Eur J Cancer. 2004 Oct;40(15):2307-16
pubmed: 15454257
Nat Rev Drug Discov. 2018 Nov 28;17(12):854-855
pubmed: 30482962
JAMA Dermatol. 2013 Aug;149(8):912-20
pubmed: 23804160
Biometrics. 2012 Mar;68(1):113-20
pubmed: 21689081
Arch Intern Med. 2006 Sep 25;166(17):1907-14
pubmed: 17000949
Cancer. 2010 May 1;116(9):2234-41
pubmed: 20187100
Anticancer Res. 2018 May;38(5):2897-2901
pubmed: 29715114
PLoS One. 2018 Jul 25;13(7):e0201034
pubmed: 30044829
Lancet. 2018 Mar 17;391(10125):1023-1075
pubmed: 29395269
J Immunother Cancer. 2018 Nov 23;6(1):128
pubmed: 30470252
J Immunother. 2020 Jan;43(1):8-15
pubmed: 31498180
J Aging Health. 2011 Dec;23(8):1263-84
pubmed: 21934120
BMC Cancer. 2016 Dec 5;16(1):936
pubmed: 27919243
Am J Med. 2010 Aug;123(8):764.e1-9
pubmed: 20670732
J Am Acad Dermatol. 2016 Feb;74(2):309-16
pubmed: 26670715